Investors: Analyst Coverage
Scott R. Henry, CFA
Roth Capital Partners
SHenry@Roth.com
949-500-0863
Yale Jen, Ph.D.
Laidlaw & Company
yjen@laidlawltd.com212-953-4978
William Maughan
Canaccord Genuity LLC (US)
wmaughan@cgf.com
212-389-8948
Marie Thibault
BTIG
mthibault@btig.com
212-527-3557
Swayampakula Ramakanth, Ph.D.
H.C. Wainwright & Co., LLC
sramakanth@hcwresearch.com
212-356-0544
Delcath Systems, Inc. (NASDAQ-DCTH) is an interventional oncology company focused on the treatment of primary and metastatic liver cancers.